This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on its slew of product launches and regulatory approvals.
United Therapeutics (UTHR) Gains on Tyvaso Label Expansion
by Zacks Equity Research
United Therapeutics' (UTHR) Tyvaso is now the only FDA-approval therapy for treating serious, life-threatening disease, pulmonary hypertension associated with interstitial lung disease.
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
Coronavirus Ups the Game for Robotic Surgery: 3 Stocks on Radar
by Sriparna Ghosal
Let's keep a watch on the potentially strong three MedTech stocks, namely SYK, ARAY and MDT with respect to robotic-assisted surgery that showed promises during the pandemic.
Medtronic (MDT) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.
The Zacks Analyst Blog Highlights: Amazon, Visa, Medtronic, American Express and Mondelez International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Visa, Medtronic, American Express and Mondelez International
Medtronic (MDT) Directional Lead for DBS System Gets CE Mark
by Zacks Equity Research
This SenSight system according to Medtronic (MDT), is set to enhance detection of local field potentials (LFPs).
Top Stock Reports for Amazon, Visa & Medtronic
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), Visa (V), and Medtronic (MDT).
4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.
Medtronic (MDT) Gets FDA Nod for Revised Neuromodulation Labeling
by Zacks Equity Research
This latest development is expected to contribute to Medtronic's (MDT) pain therapy business in the coming months.
The Zacks Analyst Blog Highlights: Abbott, Johnson & Johnson, Masimo Corp and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Johnson & Johnson, Masimo Corp and Medtronic
4 Stocks to Watch as FDA Action Plan Stresses MedTech Digitization
by Urmimala Biswas
These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.
Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF
by Zacks Equity Research
Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.
Medtronic's (MDT) HVAD Pump Kit Recall Classified as Class I
by Zacks Equity Research
The latest back-to-back incidents will, undoubtedly, create a major drag in Medtronic's (MDT) VAD performance.
Medtronic's (MDT) Market Share Grows Amid COVID-19 Woes
by Zacks Equity Research
In Coronary, the ongoing issue related to the China drug-eluting stent national tender, Medtronic (MDT) is currently winning share globally.
The Zacks Analyst Blog Highlights: Amazon, Chevron, Citigroup, Medtronic and Morgan Stanley
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Chevron, Citigroup, Medtronic and Morgan Stanley
Top Stock Reports for Amazon, Chevron & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Chevron (CVX), and Citigroup (C).
United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.
Company News for Feb 24, 2021
by Zacks Equity Research
Companies In The News Are: M, MDT, NXST, CBRE
Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Medtronic (MDT) procedure volumes hurt by resurgence of COVID-19 cases despite increased demand for related diagnostics and therapies.
Medtronic (MDT) Beats Q3 Earnings Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 12.17% and -0.03%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.
Medtronic (MDT) Progresses in SNM With Updated InterStim Label
by Zacks Equity Research
Medtronic (MDT) expects this updated labeling with wider procedural options and shorter wait time to improve patient access to MRI exams and add more flexibility for MRI providers.